

# Brian Calingaert

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/1522251/brian-calingaert-publications-by-year.pdf>

**Version:** 2024-04-29

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

67  
papers

3,040  
citations

32  
h-index

55  
g-index

73  
ext. papers

3,349  
ext. citations

3.1  
avg. IF

4.44  
L-index

#	Paper	IF	Citations
67	Evaluating patient and physician knowledge of risks and safe use of rivaroxaban: a survey across four countries. <i>Expert Opinion on Drug Safety</i> , <b>2021</b> , 1-12	4.1	
66	Long-Term Risk of Skin Cancer and Lymphoma in Users of Topical Tacrolimus and Pimecrolimus: Final Results from the Extension of the Cohort Study Protopic Joint European Longitudinal Lymphoma and Skin Cancer Evaluation (JOELLE).. <i>Clinical Epidemiology</i> , <b>2021</b> , 13, 1141-1153	5.9	1
65	Evaluation of Physician Knowledge of the Key Safety Information for Aflibercept in Canada: Evaluation of Risk-Minimization Measures. <i>Pharmaceutical Medicine</i> , <b>2019</b> , 33, 235-246	2.3	2
64	Physician and Patient Knowledge of Safety and Safe Use Information for Aflibercept in Europe: Evaluation of Risk-Minimization Measures. <i>Pharmaceutical Medicine</i> , <b>2019</b> , 33, 219-233	2.3	2
63	Incidence of Second Primary Malignancies in Patients with Castration-Resistant Prostate Cancer: An Observational Retrospective Cohort Study in the United States. <i>Prostate Cancer</i> , <b>2019</b> , 2019, 4387415	1.9	5
62	Virologic Failure Among People Living With HIV Initiating Dolutegravir-Based Versus Other Recommended Regimens in Real-World Clinical Care Settings. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2019</b> , 81, 572-577	3.1	9
61	Proportions of Cancer Cases in Primary Care, Hospital, and Cancer Registry Data Among Patients Treated for Overactive Bladder. <i>Epidemiology</i> , <b>2019</b> , 30, e8-e9	3.1	
60	A cohort study on the risk of lymphoma and skin cancer in users of topical tacrolimus, pimecrolimus, and corticosteroids (Joint European Longitudinal Lymphoma and Skin Cancer Evaluation - JOELLE study). <i>Clinical Epidemiology</i> , <b>2018</b> , 10, 299-310	5.9	49
59	Effectiveness of risk minimization measures for the use of cilostazol in United Kingdom, Spain, Sweden, and Germany. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2018</b> , 27, 953-961	2.6	2
58	Use of Topical Tacrolimus and Topical Pimecrolimus in Four European Countries: A Multicentre Database Cohort Study. <i>Drugs - Real World Outcomes</i> , <b>2018</b> , 5, 109-116	2.2	2
57	Validation of Cancer Cases Using Primary Care, Cancer Registry, and Hospitalization Data in the United Kingdom. <i>Epidemiology</i> , <b>2018</b> , 29, 308-313	3.1	35
56	Value of Free-text Comments for Validating Cancer Cases Using Primary-care Data in the United Kingdom. <i>Epidemiology</i> , <b>2018</b> , 29, e41-e42	3.1	8
55	Epidemiology of Adult Soft-Tissue Sarcomas in Germany. <i>Sarcoma</i> , <b>2018</b> , 2018, 5671926	3.1	14
54	Characterization of new users of cilostazol in the UK, Spain, Sweden, and Germany. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2017</b> , 26, 615-624	2.6	10
53	The feasibility of using multiple databases to study rare outcomes: the potential effect of long-acting beta agonists with inhaled corticosteroid therapy on asthma mortality. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2017</b> , 26, 446-458	2.6	0
52	Incidence of second primary malignancies (SPM) in men with castration-resistant prostate cancer (CRPC) in SEER-Medicare database.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, e13080-e13080	2.2	1
51	Cardiovascular risk associated with the use of glitazones, metformin and sulfonylureas: meta-analysis of published observational studies. <i>BMC Cardiovascular Disorders</i> , <b>2016</b> , 16, 14	2.3	25

50	Topiramate use during pregnancy and major congenital malformations in multiple populations. <i>Birth Defects Research Part A: Clinical and Molecular Teratology</i> , <b>2015</b> , 103, 269-75		12
49	Treatment Patterns, Costs, and Survival among Medicare-Enrolled Elderly Patients Diagnosed with Advanced Stage Gastric Cancer: Analysis of a Linked Population-Based Cancer Registry and Administrative Claims Database. <i>Journal of Gastric Cancer</i> , <b>2015</b> , 15, 87-104	3.2	18
48	Topiramate use in pregnancy and the birth prevalence of oral clefts. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2014</b> , 23, 1017-25	2.6	52
47	Risk of acute liver injury associated with the use of moxifloxacin and other oral antimicrobials: a retrospective, population-based cohort study. <i>Pharmacotherapy</i> , <b>2014</b> , 34, 336-49	5.8	20
46	Validation of acute liver injury cases in a population-based cohort study of oral antimicrobial users. <i>Current Drug Safety</i> , <b>2014</b> , 9, 23-8	1.4	9
45	The risk of heart failure associated with the use of noninsulin blood glucose-lowering drugs: systematic review and meta-analysis of published observational studies. <i>BMC Cardiovascular Disorders</i> , <b>2014</b> , 14, 129	2.3	48
44	Myocardial infarction and individual nonsteroidal anti-inflammatory drugs meta-analysis of observational studies. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2013</b> , 22, 559-70	2.6	95
43	Individual NSAIDs and upper gastrointestinal complications: a systematic review and meta-analysis of observational studies (the SOS project). <i>Drug Safety</i> , <b>2012</b> , 35, 1127-46	5.1	245
42	Incidence of osteonecrosis of the jaw among users of bisphosphonates with selected cancers or osteoporosis. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2012</b> , 21, 810-7	2.6	52
41	Maternal outcomes among pregnant women receiving live attenuated influenza vaccine. <i>Influenza and Other Respiratory Viruses</i> , <b>2012</b> , 6, 44-51	5.6	22
40	Individual NSAIDs and Upper Gastrointestinal Complications <b>2012</b> , 35, 1127-46		95
39	Patient factors associated with glucagonlike peptide 1 receptor agonist use with and without insulin. <i>Endocrine Practice</i> , <b>2011</b> , 17, 707-16	3.2	5
38	Folic acid supplementation before and during pregnancy in the Newborn Epigenetics Study (NEST). <i>BMC Public Health</i> , <b>2011</b> , 11, 46	4.1	95
37	Stroke risk and NSAIDs: a systematic review of observational studies. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2011</b> , 20, 1225-36	2.6	68
36	Use of long-acting beta-agonists and inhaled steroids in asthma: meta-analysis of observational studies. <i>Journal of Asthma</i> , <b>2010</b> , 47, 439-46	1.9	20
35	Single nucleotide polymorphisms in the TP53 region and susceptibility to invasive epithelial ovarian cancer. <i>Cancer Research</i> , <b>2009</b> , 69, 2349-57	10.1	52
34	Relationship between tamoxifen use and high risk endometrial cancer histologic types. <i>Gynecologic Oncology</i> , <b>2009</b> , 112, 150-4	4.9	55
33	The role of lymphadenectomy in the management of preoperative grade 1 endometrial carcinoma. <i>Gynecologic Oncology</i> , <b>2009</b> , 112, 511-6	4.9	50

32	Cancer genetic counseling in rural North Carolina oncology clinics: program establishment and patient characteristics. <i>Community Oncology</i> , <b>2009</b> , 6, 70-77		3
31	Attitudes regarding the use of hematopoietic colony-stimulating factors and maintenance of relative dose intensity among gynecologic oncologists. <i>International Journal of Gynecological Cancer</i> , <b>2009</b> , 19, 447-54	3.5	4
30	Bromelain treatment decreases secretion of pro-inflammatory cytokines and chemokines by colon biopsies in vitro. <i>Clinical Immunology</i> , <b>2008</b> , 126, 345-52	9	60
29	Hormonal risk factors for ovarian cancer in premenopausal and postmenopausal women. <i>American Journal of Epidemiology</i> , <b>2008</b> , 167, 1059-69	3.8	89
28	Cyclin E overexpression in epithelial ovarian cancer characterizes an etiologic subgroup. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2008</b> , 17, 585-93	4	26
27	Cyclin E Overexpression Relates to Ovarian Cancer Histology but not to Risk Factors. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2008</b> , 17, 1841.2-1842	4	
26	Polymorphism in the IL18 gene and epithelial ovarian cancer in non-Hispanic white women. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2008</b> , 17, 3567-72	4	14
25	The prognostic significance of positive peritoneal cytology and adnexal/serosal metastasis in stage IIIA endometrial cancer. <i>Gynecologic Oncology</i> , <b>2007</b> , 104, 401-5	4.9	63
24	Outcomes in surgical stage I uterine papillary serous carcinoma. <i>Gynecologic Oncology</i> , <b>2007</b> , 105, 677-82	4.9	92
23	The role of multi-modality adjuvant chemotherapy and radiation in women with advanced stage endometrial cancer. <i>Gynecologic Oncology</i> , <b>2007</b> , 107, 285-91	4.9	106
22	Trinucleotide repeat polymorphisms in the androgen receptor gene and risk of ovarian cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2007</b> , 16, 473-80	4	46
21	Pelvic lymph node count is an important prognostic variable for FIGO stage I and II endometrial carcinoma with high-risk histology. <i>Gynecologic Oncology</i> , <b>2006</b> , 102, 92-7	4.9	164
20	Analgesic drug use and risk of ovarian cancer. <i>Epidemiology</i> , <b>2006</b> , 17, 104-7	3.1	60
19	Antidepressant medication use [corrected] and risk of ovarian cancer. <i>Obstetrics and Gynecology</i> , <b>2005</b> , 105, 725-30	4.9	16
18	Menopausal hormones and risk of ovarian cancer. <i>American Journal of Obstetrics and Gynecology</i> , <b>2005</b> , 193, 76-82	6.4	25
17	Transforming growth factor beta receptor I polyalanine repeat polymorphism does not increase ovarian cancer risk. <i>Gynecologic Oncology</i> , <b>2005</b> , 97, 543-9	4.9	16
16	Resection of lymph node metastases influences survival in stage IIIC endometrial cancer. <i>Gynecologic Oncology</i> , <b>2005</b> , 99, 689-95	4.9	87
15	Anthropometric measurements and epithelial ovarian cancer risk in African-American and White women. <i>Cancer Causes and Control</i> , <b>2005</b> , 16, 955-63	2.8	37

14	Retrospective analysis of selective lymphadenectomy in apparent early-stage endometrial cancer. <i>Journal of Clinical Oncology</i> , <b>2005</b> , 23, 3668-75	2.2	347
13	Radical hysterectomy and pelvic lymphadenectomy for stage IB2 cervical cancer. <i>Gynecologic Oncology</i> , <b>2004</b> , 93, 429-34	4.9	48
12	Prospective and longitudinal patient self-assessment of health-related quality of life following radical perineal prostatectomy. <i>Journal of Urology</i> , <b>2004</b> , 172, 264-8	2.5	29
11	Characterization of prediagnostic symptoms among primary epithelial ovarian cancer cases and controls. <i>Gynecologic Oncology</i> , <b>2003</b> , 90, 75-82	4.9	60
10	Matrix Metalloproteinase-1 Gene Promoter Polymorphism and Risk of Ovarian Cancer. <i>Journal of the Society for Gynecologic Investigation</i> , <b>2003</b> , 10, 381-387		11
9	Polymorphisms in BRCA1 and BRCA2 and risk of epithelial ovarian cancer. <i>Clinical Cancer Research</i> , <b>2003</b> , 9, 4396-403	12.9	37
8	Ovulation and ovarian cancer: a comparison of two methods for calculating lifetime ovulatory cycles (United States). <i>Cancer Causes and Control</i> , <b>2002</b> , 13, 807-11	2.8	42
7	Pre-counseling education materials for BRCA testing: does tailoring make a difference?. <i>Genetic Testing and Molecular Biomarkers</i> , <b>2002</b> , 6, 93-105		55
6	Impact of progestin and estrogen potency in oral contraceptives on ovarian cancer risk. <i>Journal of the National Cancer Institute</i> , <b>2002</b> , 94, 32-8	9.7	133
5	Tag Reporting Rate Estimation: 2. Use of High-Reward Tagging and Observers in Multiple-Component Fisheries. <i>North American Journal of Fisheries Management</i> , <b>2002</b> , 22, 727-736	1.1	31
4	Tag Reporting Rate Estimation: 2. Use of High-Reward Tagging and Observers in Multiple-Component Fisheries <b>2002</b> , 22, 727		2
3	Types and duration of symptoms prior to diagnosis of invasive or borderline ovarian tumor. <i>Gynecologic Oncology</i> , <b>2001</b> , 83, 466-71	4.9	46
2	Tag Reporting Rate Estimation: 1. An Evaluation of the High-Reward Tagging Method. <i>North American Journal of Fisheries Management</i> , <b>2001</b> , 21, 521-532	1.1	111
1	Tag Reporting Rate Estimation: 1. An Evaluation of the High-Reward Tagging Method <b>2001</b> , 21, 521		2